Fighting cancer happens on multiple fronts: preventing it through daily habits, catching it early through screening, and treating it with therapies that have become remarkably precise. A healthy diet alone can prevent 30 to 50% of cancer cases, and people who maintain a healthy weight while following three or more protective lifestyle habits see their cancer mortality drop by roughly 60%. Whether you’re trying to lower your risk, navigating a diagnosis, or supporting someone who is, here’s what the evidence says works.
Lifestyle Changes That Cut Cancer Risk
The choices you make every day have a surprisingly large effect on whether cancer develops in the first place. Obesity accounts for about 5% of cancer cases in men and 10% in women. Alcohol causes roughly 4% of cancers worldwide, translating to over 740,000 cases per year. And about 12% of colorectal cancer deaths trace back to cigarette smoking.
Regular physical activity reduces the risk of developing cancer by 10 to 25%. Studies on cancer patients and survivors typically use a mix of aerobic exercise (walking, cycling, swimming) three to five times per week and resistance training twice per week, with sessions lasting 20 to 45 minutes. You don’t need to train like an athlete. Moderate-intensity exercise, the kind where you can still hold a conversation, accumulated over about 150 to 180 minutes per week, is the range most consistently linked to better outcomes.
If you’re already dealing with a diagnosis, exercise still matters. Trials have tested structured programs in cancer patients that start gently (15 minutes at a comfortable effort) and build gradually over several months. The pattern is consistent: moving your body improves survival, reduces recurrence risk, and helps manage the fatigue and mood changes that often accompany treatment.
What to Eat and Why It Matters
The Mediterranean dietary pattern has the strongest track record in cancer prevention research. It emphasizes whole grains, fruits, vegetables, olive oil, moderate amounts of fish and poultry, and very little red meat or sweets. Following this pattern can reduce the risk of breast, colorectal, and prostate cancers by 60 to 70%, and lung cancer risk by 40 to 50%.
Specific foods stand out. Cruciferous vegetables like broccoli, cabbage, and Brussels sprouts contain compounds that help cells repair DNA damage. Garlic has shown protective effects across several cancer types. Foods rich in fiber, particularly whole grains, and those high in selenium, folate, vitamin D, and antioxidants like lycopene (found in tomatoes and watermelon) and carotenoids (found in carrots, sweet potatoes, and dark leafy greens) all contribute to a lower overall cancer risk. A moderate intake of dairy may also help reduce incidence of colorectal, lung, stomach, and breast cancers.
Screening That Catches Cancer Early
Early detection dramatically changes outcomes. Many cancers are highly treatable when found before symptoms appear, which is why screening guidelines exist for the most common types.
- Breast cancer: Mammography every two years for women aged 40 to 74.
- Colorectal cancer: Screening starting at age 45, continuing through age 75. Options include stool-based tests and colonoscopy.
- Cervical cancer: Pap smears every three years for women aged 21 to 29. From age 30 to 65, screening every three years with a Pap smear, every five years with HPV testing, or every five years with both.
- Lung cancer: Annual low-dose CT scans for adults aged 50 to 80 who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years.
Blood-based cancer detection tests, often called liquid biopsies, are an emerging option. One of the most studied, the Galleri test, screens for signals from over 50 cancer types with a 99.5% specificity, meaning very few false alarms. But its sensitivity for stage I cancers is only about 17%, so it catches early-stage disease less reliably. These tests currently serve as supplements to standard screening, not replacements.
When Genetics Play a Role
About 5 to 10% of cancers are driven by inherited gene changes. Genetic testing is recommended for anyone diagnosed with triple-negative breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer before age 50, metastatic prostate cancer, or male breast cancer. Beyond those diagnoses, certain family patterns should prompt a conversation about testing: a first-degree relative with a known cancer-risk gene, multiple family members with the same cancer type, cancer diagnosed unusually young, cancer in both of a paired organ (both breasts, both kidneys), or a combination of breast or ovarian cancer with colon or endometrial cancer in the same family.
If testing reveals a harmful genetic variant, it doesn’t mean cancer is inevitable. It means you and your medical team can pursue more aggressive screening schedules and, in some cases, preventive interventions that significantly lower your risk.
How Modern Treatment Works
Cancer treatment has moved well beyond a single approach. Most people receive a combination tailored to their specific cancer type, stage, and biology.
Surgery physically removes the tumor and remains the most direct option when cancer is localized. Radiation therapy uses high-energy beams to destroy cancer cells or shrink tumors, often targeting a specific area to minimize damage to healthy tissue. Chemotherapy kills fast-growing cells throughout the body and is used when cancer may have spread or is likely to.
Hormone therapy slows or stops the growth of breast and prostate cancers that rely on hormones as fuel. Targeted therapy is more precise: it goes after specific molecular changes inside cancer cells that allow them to grow and divide. Because it focuses on those changes, it often causes fewer side effects than chemotherapy.
Immunotherapy
One of the biggest shifts in cancer treatment over the past decade is immunotherapy, which trains your own immune system to recognize and attack cancer. Cancer cells are sneaky. They produce proteins on their surface that bind to “checkpoint” proteins on immune cells called T cells, essentially sending an “off” signal that prevents the immune system from attacking. Checkpoint inhibitor drugs block that handshake, keeping the T cells switched on so they can find and destroy cancer cells.
Another form, called CAR-T cell therapy, involves removing a patient’s T cells, engineering them in a lab to recognize a specific protein on the cancer, and infusing them back into the body. This approach has produced remarkable responses in certain blood cancers.
Finding a Clinical Trial
Clinical trials offer access to treatments that aren’t yet widely available, and for some patients they represent the best option. The process starts with gathering details about your specific diagnosis: cancer type, stage, prior treatments, and relevant biomarkers. Your oncologist can often identify trials that fit your situation.
If you want to search on your own, the NCI’s clinical trials search tool lists government-funded trials across the United States and internationally. ClinicalTrials.gov, run by the National Library of Medicine, is the broadest database, listing trials funded by nonprofits, drug companies, and academic medical centers. Cancer advocacy organizations for specific cancer types also maintain trial listings. Once you find a potential match, contact the trial coordinator directly. The phone number is listed in the trial summary.
You can also call the NCI’s Cancer Information Service at 1-800-422-6237 and select option 2 for a personalized search.
Palliative Care Improves Quality of Life
Palliative care is not the same as hospice. It’s specialized medical care focused on relieving symptoms, managing pain, and improving quality of life at any stage of cancer, including during active treatment. In a trial of 350 patients with advanced lung or gastrointestinal cancers, those who received monthly palliative care visits alongside their standard treatment reported better quality of life, improved mood, and were more likely to develop effective coping strategies over the following six months.
Patients in the palliative care group were also more than twice as likely to have had conversations about their care preferences: 30% compared to just 14% receiving standard care alone. Starting palliative care early, rather than waiting until treatment options narrow, consistently leads to better emotional and physical well-being throughout the treatment process.